Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial

Back

ESC2025 Premium Access

Empagliflozin significantly reduces the capacity of sera to induce endothelial dysfunction in Ischemia Non-Obstructive Coronary Arteries (INOCA): EMbArk phase II pilot trial

Session: Women's cardiovascular disease and pregnancy

Topic: Cardiovascular Disease in Women

Speaker: Doctor O. Quesada (Cincinnati, US)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Odayme Quesada

The Christ Hospital Health Network, Cincinnati (United States of America)

0 follower

6 more presentations in this session

Risks of antihypertensive treatment use in different periods of pregnancy

Speaker: Professor J. Vaclavik (Ostrava, CZ)

Risk factors and prediction model for hypertension in women with hyperandrogenic phenotypes of polycystic ovary syndrome

Speaker: Doctor A. Stevanovic (Belgrade, RS)

Sex differences in trajectory of left ventricular reverse remodelling under contemporary GDMT in recent-onset dilated cardiomyopathy

Speaker: Doctor Z. Yang (Sichuan, CN)

Improving hypertension management in Egyptian women through standardised nurse training on blood pressure measurement

Speaker: Professor R. Hany Ibrahim (Cairo, EG)

Exploring the relationship between testosterone and cardiovascular disease in women

Speaker: Doctor S. Alexander (Melbourne, AU)

Access the full session

Women's cardiovascular disease and pregnancy

Speakers: Doctor O. Quesada, Professor J. Vaclavik, Doctor A. Stevanovic, Doctor Z. Yang, Professor R. Hany Ibrahim...

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources